Sarah Westall - Business Game Changers

Sarah Westall - Business Game Changers


The Situation is Serious, So it’s Time for You to get Serious Too w/ Dr. Joe Neusma

November 28, 2022

Dr. Joe Neusma returns to the program to discuss the solutions to the health crisis we are in. We discuss solutions that range from staying healthy to healing from blood clots to determining your weakest health risk. We are in a serious situation and it is time for all of us to be serious about our health and the solutions that exist. Learn more about Dr. Joe Neusma at SuperiorToxicology.com

 

 
See Important Proven Solutions to Keep Your from getting sick even if you had the mRNA Shot - Dr. Nieusma
Get Dr. Zelenko's Z-stack or the new formulated Z-Flu at https://zstacklife.com/?ref=Sarah - Use code "Fall10" to save 10%
Protect your family and your assets with Silver & Gold - Contact info@milesfranklin.com, tell them "Sarah sent you" and receive excellent service and the lowest prices in the country, guaranteed!
Learn more about the Nobel prize winning technology behind Govvi & how to save serious money on Gas: GOVVI.com/go/helpmesave
MUSIC CREDITS: "Silent Bleak Night" by Human's Win and "Do You Trust Me" by Michael Vignola, licensed for broad internet media use, including video and audio
 

See on Odysee | Bitchute | Rumble | SarahWestall.tv | Freedom.Social

 

 
Dr. Joe Nieusma Biography
Dr. Joe Nieusma is our fearless CEO/Chief Toxicologist here at Superior Toxicology & Wellness, an international scientific consulting firm that he founded. Dr. Nieusma is also a co-founder for TwinOxide North America, a company working to improve water quality in all aspects of life from municipal treatment plants to livestock operations. TwinOxide removes all carcinogens from treated water and is the right thing to do.

Dr. Nieusma is a member of the Scientific Advisory Board for Vitro Biopharma, a firm that brings new stem-cell related products for diabetes research to scientific, pharmaceutical, and ultimately medical markets.  Dr. Nieusma is also on the editorial staff for the peer-reviewed scientific journal, Toxicology Mechanisms and Methods, published by Informa Healthcare.

Dr. Nieusma was a Senior Toxicologist for Affygility Solutions from October 2005 to February 2018. Affygility is a company providing strategic environmental health and safety solutions to life science companies.  Dr. Nieusma left Affygility to focus on Superior Toxicology & Wellness, as well as TwinOxide-Colorado. Dr. Nieusma was an Industrial Toxicologist for Sandoz (formerly Geneva Pharmaceuticals) from May of 1998 to April of 2004. He left Sandoz to open Superior Toxicology & Wellness. Dr. Nieusma has participated as an editorial board member for Micromedex, Inc. since May of 2001 primarily to provide toxicological evaluation of potential new products and databases as needed.  Dr. Nieusma has participated in research for a human health risk assessment involving over 100 chemicals of interest from a US Naval incinerator in Osaka, Japan. Dr. Nieusma worked for Dow Chemical in the Biotransformation group from September 1989 until July 1991.

Dr. Nieusma earned his B.S. from Central Michigan University with a major in pre-med biology and a minor in chemistry.  He went on to earn a Ph.D. in Pharmaceutical Sciences from the University of Colorado, School of Pharmacy and the Molecular Toxicology and Environmental Health Sciences Program.  The title of his dissertation research is “Stereochemical aspects of 1,3-Butadiene Metabolism and Toxicity”. His research characterized the very different pattern of metabolism and toxicity mainly due to the orientation of various side chains around chiral carbons of a small molecule hydrocarbon with multiple double bonds.

Dr. Nieusma has been actively involved in toxicology research for the past 30 years with six published manuscripts. The majority of his work, especially in the pharmaceutical industry and consulting, has been conducted in an industrial setting and published only within the company or to a client. These potent compound classification reports for pharmaceutical agents...